IRVING,
Texas and MONROVIA,
Calif., Jan. 5, 2023 /PRNewswire/ -- Caris Life
Sciences®(Caris), the leading molecular science and
technology company actively developing and delivering innovative
solutions to revolutionize healthcare, and Xencor,
Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical
company developing engineered antibodies and cytokines for the
treatment of cancer and autoimmune diseases, today announced an
expansion of their collaboration to research, develop and
commercialize novel XmAb® bispecific and multi-specific antibodies
directed against novel targets, identified and proposed by Caris,
for the treatment of patients with cancer.
Building upon the initial August
2022 agreement, this expanded collaboration will increase
the number of targets and cancer types that Caris will interrogate
with its proprietary, multi-omics discovery engine platform, Caris
Discovery. Novel targets and their accompanying validation packages
will serve as the substrate for drug candidate development through
Xencor's XmAb platform.
"Xencor has an impressive track record of advancing drug
development programs from early discovery through to the clinic,
and we are excited to bring forward additional novel targets for
their team," said David Spetzler,
M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris
Life Sciences. "The aggregate strength of Caris' platform permits
the unlocking of otherwise inaccessible targets, and we look
forward to realizing our shared goal of bringing novel
antibody-directed therapies to patients with cancer."
"We are committed to leveraging our XmAb bispecific antibody
platforms, building an internal portfolio of novel drug candidates
and advancing potentially transformational treatment options for
patients," said John Desjarlais,
Ph.D., Senior Vice President and Chief Scientific Officer of
Xencor. "Our new agreement with Caris expands a progressing
collaboration centered on their innovative target discovery and
precision oncology capabilities."
Under the terms of the new agreement, Xencor will receive
exclusive worldwide rights to research, develop and commercialize
products directed to up to three targets discovered under the
collaboration. Caris will receive an upfront payment and will be
eligible to receive up to $187
million in development and commercial milestone payments.
Caris will also be eligible to receive royalties on net sales of
commercialized products resulting from the collaboration as well as
future rights for molecular profiling and companion
diagnostics.
Caris Discovery leverages the aggregate strength of Caris'
unmatched platform, combining insights generated from the molecular
interrogation of primary patient tissues using ADAPT™, the
company's exclusive aptamer-based proteomic profiling platform; a
robust validation pipeline; and the company's proprietary
real-world data platform that integrates Caris' extensive catalog
of molecular and clinical data. Learn more about Caris Discovery
here.
XmAb® is a registered trademark of Xencor,
Inc.
About Caris Life
Sciences
Caris Life Sciences® (Caris) is the leading molecular science
and technology company actively developing and delivering
innovative solutions to revolutionize healthcare and improve
patient outcomes. Through comprehensive molecular profiling (Whole
Exome and Whole Transcriptome Sequencing) and the application of
advanced artificial intelligence (AI) and machine learning
algorithms, Caris has created the large-scale clinico-genomic
database and cognitive computing needed to analyze and unravel the
molecular complexity of disease. This information provides an
unmatched resource and the ideal path forward to conduct the basic,
fundamental research to accelerate discovery for detection,
diagnosis, monitoring, therapy selection and drug development to
improve the human condition.
With a primary focus on cancer, Caris' suite of market-leading
molecular profiling offerings assesses DNA, RNA and proteins to
reveal a molecular blueprint that helps patients, physicians and
researchers better detect, diagnose and treat patients. Caris'
latest advancement is a blood-based, circulating nucleic acids
sequencing (cNAS) assay that combines comprehensive molecular
analysis (Whole Exome and Whole Transcriptome Sequencing from
blood) and serial monitoring – making it the most powerful liquid
biopsy assay ever developed.
Headquartered in Irving, Texas,
Caris has offices in Phoenix, New
York, Denver, Tokyo, Japan and Basel, Switzerland. Caris provides services
throughout the U.S., Europe,
Asia and other international
markets. To learn more, please
visit CarisLifeSciences.com or follow us on LinkedIn.
About Xencor
Xencor is a clinical-stage biopharmaceutical company
developing engineered antibodies and cytokines for the treatment of
patients with cancer and autoimmune diseases. More than 20
candidates engineered
with Xencor's XmAb® technology are in
clinical development, and three XmAb medicines are marketed by
partners. Xencor's XmAb engineering technology enables
small changes to a protein's structure that result in new
mechanisms of therapeutic action. For more information, please
visit www.xencor.com.
Xencor Forward-Looking
Statements
Certain statements contained in this press release may
constitute forward-looking statements within the meaning of
applicable securities laws. Forward-looking statements include
statements that are not purely statements of historical fact, and
can generally be identified by the use of words such as
"potential," "can," "will," "plan," "may," "could," "would,"
"expect," "anticipate," "seek," "look forward," "believe,"
"committed," "investigational," and similar terms, or by express or
implied discussions relating to the discovery of novel targets for
product candidates, the research, development or commercialization
of products or product candidates, the quotations from Xencor's
senior vice president and chief scientific officer and Caris Life
Sciences' president and chief scientific officer, and other
statements that are not purely statements of historical fact. Such
statements are made on the basis of the current beliefs,
expectations, and assumptions of the management of Xencor and are
subject to significant known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements and the timing of events to be materially different
from those implied by such statements, and therefore these
statements should not be read as guarantees of future performance
or results. Such risks include, without limitation, the risks
associated with the process of discovering, developing,
manufacturing and commercializing drugs that are safe and effective
for use as human therapeutics and other risks, including the
ability of publicly disclosed preliminary clinical trial data to
support continued clinical development and regulatory approval for
specific treatments, in each case as described in Xencor's public
securities filings. For a discussion of these and other factors,
please refer to Xencor's annual report on Form 10-K for the year
ended December 31, 2021 as well as
Xencor's subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, as amended to
date. All forward-looking statements are qualified in their
entirety by this cautionary statement and Xencor undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof, except as required by
law.
# # #
Caris Life Sciences Media Contact:
Lisa Burgner
CorpComm@carisls.com
214.294.5606
Xencor Investor Contact:
Charles Liles
cliles@xencor.com
626.737.8118
Xencor Media Contact:
Jason I.
Spark
Canale Communications
jason@canalecomm.com
619.849.6005
View original content to download
multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-and-xencor-expand-target-discovery-collaboration-for-novel-xmab-antibody-drug-candidates-301714021.html
SOURCE Caris Life Sciences